Pharsight

Drugs that contain Meloxicam

1. Anjeso patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727 BAUDAX Nanoparticulate meloxicam formulations
Dec, 2022

(1 year, 3 months ago)

US10463673 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(a month ago)

US10471067 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(a month ago)

US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(6 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(6 years from now)

US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(14 years from now)

US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 20, 2023

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

Family Patents

2. Meloxicam patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6184220 AVONDALE PHARMS Oral suspension of pharmaceutical substance
Mar, 2019

(5 years ago)

US6184220

(Pediatric)

AVONDALE PHARMS Oral suspension of pharmaceutical substance
Sep, 2019

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Feb 11, 2013
Orphan Drug Exclusivity(ODE) Aug 11, 2012

Market Authorisation Date: 01 June, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of MELOXICAM before it's drug patent expiration?
More Information on Dosage

MELOXICAM family patents

Family Patents

3. Qmiiz Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam
Aug, 2030

(6 years from now)

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

QMIIZ ODT family patents

Family Patents

4. Vivlodex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2033

(8 years from now)

US9808468 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(10 years from now)

US9649318 ICEUTICA OPERATIONS Formulation of meloxicam
Mar, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 22, 2018

Market Authorisation Date: 22 October, 2015

Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam

Dosage: CAPSULE;ORAL

How can I launch a generic of VIVLODEX before it's drug patent expiration?
More Information on Dosage

VIVLODEX family patents

Family Patents